These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21954818)

  • 1. [Anticancer drugs under pressure].
    Ben Aïssa A; George AC; El M'Rabet FZ; Mach N; Dietrich PY; Pechère-Bertschi A
    Rev Med Suisse; 2011 Sep; 7(308):1761-6. PubMed ID: 21954818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
    Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
    J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
    Horsley L; Marti K; Jayson GC
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
    Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
    Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
    Vigneau C; Rioux-Leclercq N
    Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal effects of anti-angiogenesis therapy: update for the internist.
    Gurevich F; Perazella MA
    Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-vascular endothelial growth factor (VEGF) therapy: a new cause of secondary hypertension].
    Hertig A
    Rev Prat; 2010 May; 60(5):644-5, 647-8. PubMed ID: 20564846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review.
    Boehm S; Rothermundt C; Hess D; Joerger M
    Gerontology; 2010; 56(3):303-9. PubMed ID: 19940466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
    Cosmai L; Gallieni M; Liguigli W; Porta C
    J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
    van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
    J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
    [No Abstract]   [Full Text] [Related]  

  • 12. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
    Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
    Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of novel angiogenesis inhibitors targeting VEGF (vascular endothelial growth factor) for cancer chemotherapy].
    Kakeya H; Osada H
    Nihon Rinsho; 2004 Jul; 62(7):1264-70. PubMed ID: 15283142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF-targeted therapy: mechanisms of anti-tumour activity.
    Ellis LM; Hicklin DJ
    Nat Rev Cancer; 2008 Aug; 8(8):579-91. PubMed ID: 18596824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction of radiation therapy and antiangiogenic therapy.
    O'Reilly MS
    Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncontrolled Hypertension and Oncology: Clinical Tips.
    Kalaitzidis RG; Elisaf MS
    Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.
    Steeghs N; Gelderblom H; Roodt JO; Christensen O; Rajagopalan P; Hovens M; Putter H; Rabelink TJ; de Koning E
    Clin Cancer Res; 2008 Jun; 14(11):3470-6. PubMed ID: 18519779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.